{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:22:53Z","timestamp":1772450573855,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Cancer Institute Cancer Center","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B\u2010cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors conducted a single\u2010arm, phase 2 trial of combined temsirolimus and bortezomib in patients with relapsed and refractory B\u2010cell non\u2010Hodgkin lymphoma (NHL) using a dosing scheme that was previously tested in multiple myeloma. The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35\u2010day cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 39 patients who received treatment, 3 achieved a complete response (7.7%; 95% confidence interval [CI], 1.6%\u201021%), and 9 had a partial response (PR) (23%; 95% CI, 11%\u201039%). Thus, the overall response rate (12 of 39 patients) was 31% (95% CI, 17%\u201048%), and the median progression\u2010free survival was 4.7 months (95% CI, 2.1\u20107.8 months; 2 months for patients with diffuse large B\u2010cell lymphoma [n = 18], 7.5 months for those with mantle cell lymphoma [n = 7], and 16.5 months for those with follicular lymphoma [n = 9]). Two extensively treated patients with diffuse large B\u2010cell lymphoma achieved a complete response. There were no unexpected toxicities from the combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current results demonstrate that the combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in patients with heavily pretreated B\u2010cell NHL. Further studies with this combination are warranted in specific subtypes of NHL. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:3435\u201343.<\/jats:bold> \u00a9 <jats:italic>2015 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29502","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T12:15:12Z","timestamp":1434456912000},"page":"3465-3471","source":"Crossref","is-referenced-by-count":32,"title":["A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B\u2010cell non\u2010Hodgkin lymphoma: A Wisconsin Oncology Network study"],"prefix":"10.1002","volume":"121","author":[{"given":"Timothy S.","family":"Fenske","sequence":"first","affiliation":[{"name":"Division of Hematology &amp; Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata M.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Mann","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle E.","family":"Baim","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Farnen","sequence":"additional","affiliation":[{"name":"Gundersen Lutheran Health System La Crosse Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adedayo A.","family":"Onitilo","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Weston Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules H.","family":"Blank","sequence":"additional","affiliation":[{"name":"St. Vincent Regional Cancer Center Green Bay Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Aspirus Regional Cancer Center Wausau Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Wassenaar","sequence":"additional","affiliation":[{"name":"ProHealth Care Cancer Center Waukesha Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubina","family":"Qamar","sequence":"additional","affiliation":[{"name":"Aurora Cancer Care Wauwatosa Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mansky","sequence":"additional","affiliation":[{"name":"Bellin Health Green Bay Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Traynor","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J.","family":"Mattison","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.10.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07466.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13065"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2882"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70028-6"},{"key":"e_1_2_7_17_1","unstructured":"US Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published May 29 2009; Updated 2009. Available at:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201006\u201014_QuickReference_8.5x11.pdf. Accessed April 13 2014."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205299110"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1707-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.255"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2013.08.003"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.008"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12780"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12845"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29502","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:17:10Z","timestamp":1760260630000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/cncr.29502"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29502","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]}}}